---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-039520"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2025-03-14T23:59:59+00:00"
generated_at: "2026-05-24T18:43:54.390354+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Acrivon appoints Adam Levy as CFO; Rasmus Holm-Jorgensen steps down effective April 1, 2025

## Summary
- Rasmus Holm-Jorgensen resigns as CFO effective April 1, 2025, for personal reasons to pursue Europe-based opportunity; no disagreement.
- Adam Levy, current SVP Corporate Affairs & Investor Relations, appointed CFO effective April 1, 2025.
- Levy's annual base salary set at $490,000, bonus target 40%, plus 35,209 stock options vesting over 4 years.
- Levy has over 25 years biopharma finance/IR experience, previously at Gilead, Turning Point Therapeutics, Zentalis.
- Levy required to relocate to Boston area within 9 months; up to $50,000 relocation reimbursement with 24-month clawback.

## SEC filing metadata
- accession: 0000950170-25-039520
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2025-03-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000095017025039520/0000950170-25-039520-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000095017025039520/acrv-20250311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-039520
- JSON: https://secwatch.observer/filing/0000950170-25-039520.json
- Plain text: https://secwatch.observer/filing/0000950170-25-039520.txt

## Key facts
- Executive change
  Rasmus Holm-Jorgensen resigned as Chief Financial Officer at Acrivon Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On March 11, 2025, Rasmus Holm-Jorgensen, the Company’s Chief Financial Officer, notified the Company of his decision to step down from his position, effective April 1, 2025, for personal reasons to pursue another opportunity with a company based in Europe, allowing him to spend more time near his family.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781174/000095017025039520/0000950170-25-039520-index.htm
- Executive change
  Adam Levy was appointed as Chief Financial Officer at Acrivon Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On March 14, 2025, Acrivon Therapeutics, Inc. (the “Company”) appointed Adam Levy, Ph.D., M.B.A., to the position of Chief Financial Officer, effective as of April 1, 2025 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781174/000095017025039520/0000950170-25-039520-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.